Inc. (NASDAQ:INCR) Files An 8-K Financial Statements and ExhibitsItem 9.01. Financial Statements and Exhibits.
| (d) | Exhibits. |
| 4.1* | Form of Warrant, to be issued by PLx Pharma Inc. to the Investors on June 14, 2017. |
| 5.1* | Opinion of Jackson Walker L.L.P. |
|
10.1† |
Amended and Restated Patent License Agreement, dated December 11, 2009 |
|
10.2† |
Amendment No. 1 to Amended and Restated Patent License Agreement, dated April 15, 2011 |
|
10.3* |
Amendment No. 2 to Amended and Restated Patent License Agreement, dated December 17, 2011 |
| 23.1* | Consent of Jackson Walker L.L.P. (included in Exhibit 5.1) |
| 99.1* | Press Release, issued by PLx Pharma Inc. on June 12, 2017 |
| 99.2* | Placement Agency Agreement, dated as of June 9, 2017, by and between PLx Pharma Inc. and Raymond James & Associates, Inc. |
| 99.3* | Form of Securities Purchase Agreement |
| * Filed as exhibit to Original Form 8-K filed with the Securities and Exchange Commission on June 12, 2017 | |
| †Confidential treatment requested. |
PLx Pharma Inc. ExhibitEX-10.1 2 ex10-1.htm EXHIBIT 10.1 ex10-1.htm Exhibit 10.1 AMENDED AND RESTATED PATENT LICENSE AGREEMENT BETWEEN THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM AND PLX PHARMA INC. DATED DECEMBER 11,…To view the full exhibit click here
About Inc. (NASDAQ:INCR)
INC Research Holdings, Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services. The Company’s Clinical Development Services segment offers all clinical development services, including full-service global studies, as well as ancillary services, such as clinical monitoring, investigator recruitment, patient recruitment, data management, study reports to assist customers with their drug development process, quality assurance audits and specialized consulting services. The Company’s Phase I Services segment focuses on clinical development services for Phase I trials, which include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds.
